The sNDA for DOXIL was submitted to the FDA in September 2008 . DOXIL currently is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after prior platinum-based therapy . DOXIL in combination with bortezomib is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy . DOXIL is also indicated for the treatment of AIDS-related Kaposi 's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy .